Continuous low-dose oral chemotherapy for adjuvant therapy of splenic hemangiosarcoma in dogs.

Continuous low-dose oral chemotherapy for adjuvant therapy of splenic hemangiosarcoma in dogs. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Continuous low-dose oral chemotherapy for adjuvant therapy of splenic hemangiosarcoma in dogs. Abstract Text:

Susan Lana,Lance U'ren,Susan Plaza,Robyn Elmslie,Daniel Gustafson,Paul Morley,Steven Dow,

BACKGROUND: Hemangiosarcoma (HSA) is a highly metastatic and often rapidly fatal tumor in dogs. At present, conventional adjuvant chemotherapy provides only a modest survival benefit for treated dogs. Continuous oral administration of low-dose chemotherapy (LDC) has been suggested as an alternative to conventional chemotherapy protocols. Therefore, we evaluated the safety and effectiveness of LDC using a combination of cyclophosphamide, etoposide, and piroxicam as adjuvant therapy for dogs with stage II HSA. HYPOTHESIS: We hypothesized that oral adjuvant therapy with LDC could be safely administered to dogs with HSA and that survival times would be comparable to those attained with conventional doxorubicin (DOX) chemotherapy. ANIMALS: Nine dogs with stage II splenic HSA were enrolled in the LDC study. Treatment outcomes were also evaluated retrospectively for 24 dogs with stage II splenic HSA treated with DOX chemotherapy. METHODS: Nine dogs with stage II splenic HSA were treated with LDC over a 6-month period. Adverse effects and treatment outcomes were determined. The pharmacokinetics of orally administered etoposide were determined in 3 dogs. Overall survival times and disease-free intervals were compared between the 9 LDC-treated dogs and 24 DOX-treated dogs. RESULTS: Dogs treated with LDC did not develop severe adverse effects, and long-term treatment over 6 months was well-tolerated. Oral administration of etoposide resulted in detectable plasma concentrations that peaked between 30 and 60 minutes after dosing. Both the median overall survival time and the median disease-free interval in dogs treated with LDC were 178 days. By comparison, the overall survival time and disease-free interval in dogs treated with DOX were 133 and 126 days, respectively. CONCLUSIONS: Continuous orally administered LDC may be an effective alternative to conventional high-dose chemotherapy for adjuvant therapy of dogs with HSA.

Continuous low-dose oral chemotherapy for adjuvant therapy of splenic hemangiosarcoma in dogs. Publishing Authors By Initials

S Lana,L U'ren,S Plaza,R Elmslie,D Gustafson,P Morley,S Dow,

For similar neoplasms: neoplasms by site: splenic neoplasms research abstracts see: neoplasms: neoplasms by site: splenic neoplasms research

PUBMED ID PMID:

MEDLINE DATE:

Continuous low-dose oral chemotherapy for adjuvant therapy of splenic hemangiosarcoma in dogs. Journal Published:

PUBLICATION TYPE: Research Support, N.I.H., Extr

Journal: Journal of veterinary internal medicine / American

VOLUME: 21

Page Numbers: 764-9

Journal Abbreviation: J. Vet. Intern. Med.

ISSN: 0891-6640

DAY: 3

MONTH: 12

YEAR: 2007

Continuous low-dose oral chemotherapy for adjuvant therapy of splenic hemangiosarcoma in dogs. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 8708660

Continuous low-dose oral chemotherapy for adjuvant therapy of splenic hemangiosarcoma in dogs. Keywords Mesh Terms:

KEYWORDS: Splenic Neoplasms

MESH TERMS: veterinary

Chemical & Substance for Abstract: Continuous low-dose oral chemotherapy for adjuvant therapy of splenic hemangiosarcoma in dogs. Information

Substance Name: Etoposide

Registry Number: 33419-42-0

Grant and Affiliation Information for Continuous low-dose oral chemotherapy for adjuvant therapy of splenic hemangiosarcoma in dogs.

AFFILIATION: Animal Cancer Center, Department of Clinical Sciences , Colorado State University, Ft. Collins, 80523, USA.

Country: United States

AGENCY: United States NCRR

GRANT: RR00707

ACRONYM: RR

MEDLINETA: J Vet Intern Med

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Continuous low-dose oral chemotherapy for adjuvant therapy of splenic hemangiosarcoma in dogs Related Publications

• Action potentials of cerebellar cortex in response to local electrical stimulation.
• Carbon monoxide exposure on denali: comparing the 2004 and 2005 climbing seasons.
• Complementary global maps for orientation coding in upper and lower layers of the monkey's foveal striate cortex.
• Continuous low-dose oral chemotherapy for adjuvant therapy of splenic hemangiosarcoma in dogs.
• Corticotropin releasing hormone modulates endotoxin-induced inflammatory cytokine expression in human trophoblast cells.
• Diarrheal disease control studies; conical net for collecting flies.
• Diversification of the Function of Cell-to-Cell Signaling in Regulation of Virulence Within Plant Pathogenic Xanthomonads.
• EXTRINSIC REGULATORY MECHANISMS OF SEIZURE ACTIVITY.
• Evaluation of a novel tumor vaccine in dogs with hemangiosarcoma.
• Evaluation of a xenogeneic VEGF vaccine in dogs with soft tissue sarcoma.
• Excitability of skeletal muscle during development, denervation, and tissue culture.
• Foveal tracking cells in the superior temporal sulcus of the macaque monkey.
• Indications for steroid anaesthesia.
• Infants' early ability to segment the conversational speech signal predicts later language development: a retrospective analysis.
• Integrative physiology, functional genomics and the phenotype gap: a guide for comparative physiologists.
• Interspecies signalling via the Stenotrophomonas maltophilia diffusible signal factor influences biofilm formation and polymyxin tolerance in Pseudomonas aeruginosa.
• Intradural chordoma.
• Liposome-nucleic acid immunotherapeutics.
• Mefloquine-induced disruption of calcium homeostasis in Mammalian cells is similar to that induced by ionomycin.
• Neutrophil function in septic dogs.
• Oxidative stress during acute FIV infection in cats.
• Permanent transvenous dual-chamber pacing using the coronary sinus in a patient with a mechanical prosthetic tricuspid valve.
• Stance dependence of automatic postural adjustments in humans.
• Sustained generation of tissue dendritic cells from cats using organ stromal cell cultures.
• The effect of prolonged veno-arterial pumping on the circulation of the dog.
• The establishment clause argument for choice.
• Treatment of cerebral palsy; clinical study in use of d-tubocurarine in peanut oil and myricin.
• Use of FoxP3 expression to identify regulatory T cells in healthy dogs and dogs with cancer.
• Use of radium in treatment of hypertrophic lymphoid tissue in the nasopharynx.
• Vaccination with liposome--DNA complexes elicits enhanced antitumor immunity.